Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121
Key Highlights
- ➤KRRO-121 first cohort dosed in Phase 1/2 ANCHOR trial
- ➤2mg/kg single dose administered to first healthy-volunteer cohort
- ➤ANCHOR Phase 1 plans up to 50 healthy volunteers across SAD and MAD studies
- ➤UCD patient dosing expected in first half of 2027
- ➤Interim UCD clinical readout expected in second half of 2027
Expert Statements
Ram Aiyar, Chief Executive Officer and President of Korro Bio
“UCD patients and their families live with a constant, low-grade fear that a stomach bug, a skipped dose of a nitrogen scavenger or just the wrong meal could trigger a hyperammonemic crisis. In multiple preclinical studies with different mutations, KRRO-121 has demonstrated the ability to blunt ammonia excursions”
Ram Aiyar, Chief Executive Officer and President of Korro Bio
“Dosing the first cohort in ANCHOR is a step towards gaining evidence on safety first and then activity. Providing the potential for peace of mind for patients with a UCD, irrespective of their mutational background, is something we hope to demonstrate through this trial. I would like to thank all the stakeholders involved in making this possible and working with us to provide options for patients living with UCD.”
* Initiated a Phase 1/2 clinical trial to enroll healthy volunteers and patients with Urea Cycle Disorders of any mutational background * Administered a single dose of 2mg/kg to the first cohort of healthy volunteers * Expected to start dosing in UCD patients in the first half of 2027 with an interim readout expected in the second half of 2027 CAMBRIDGE, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging its oligonucleotide promoted editing of RNA (OPERA(®)) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, announced today that the first cohort of participants has been dosed in its Phase 1/2 clinical trial for KRRO-121, the Company’s GalNAc-conjugated RNA-editing oligonucleotide (REO) in development for the potential treatment of hyperammonemia in patients with urea cycle disorders (UCDs) and patients with hepatic encephalopathy (HE).
Get started
Create a free account to read the full story.